Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a pioneering biotechnology company based in Waltham, Massachusetts, that is dedicated to developing therapeutic solutions for genetically driven muscle diseases. Founded in 2017, Dyne Therapeutics leverages its proprietary FORCE™ platform to overcome the delivery challenges associated with modern oligonucleotide therapeutics, aiming to provide life-transforming treatments for patients.
Dyne's primary focus is on advancing therapeutics for muscle disorders such as Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Muscular Dystrophy (FSHD). The company’s lead programs include DYNE-101 for DM1 and DYNE-251 for DMD, both of which have shown promising clinical results. Recent clinical trials have demonstrated dose-dependent splicing correction, improvement in muscle strength, and favorable safety profiles.
In January 2024, Dyne announced the successful completion of a $345 million public offering, extending its cash runway through 2025. This funding enables the company to advance its clinical programs and pursue expedited regulatory pathways to bring its therapies to market more swiftly.
Dyne’s recent milestones include:
- Positive clinical data from the Phase 1/2 ACHIEVE trial of DYNE-101 in DM1 patients, showing dose-dependent muscle delivery and splicing correction.
- Meaningful improvement in functional endpoints and dystrophin expression in the Phase 1/2 DELIVER trial of DYNE-251 in DMD patients.
- Ongoing efforts to enhance dosing regimens and seek accelerated approval pathways with global regulatory authorities.
With a robust pipeline and a dedicated team, Dyne is committed to addressing the unmet needs of patients with rare muscle diseases, aiming to transform their treatment landscape and improve their quality of life.
Dyne Therapeutics, a clinical-stage muscle disease company (Nasdaq: DYN), announced participation in several upcoming investor conferences. Management will engage in virtual fireside chats at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 2:40 p.m. ET; Stifel 2023 CNS Days on March 29, 2023, at 11:30 a.m. ET; and Guggenheim Genomic Medicines and Rare Disease Days on April 4, 2023, at 10:10 a.m. ET. live webcasts of these presentations will be available on the company’s website, with replays accessible for 90 days. Dyne focuses on innovative therapeutics for genetically driven muscle diseases, leveraging its FORCE™ platform.
On March 2, 2023, Dyne Therapeutics reported its fourth quarter and full year 2022 financial results, highlighting progress in its clinical trials for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). The company holds a cash position of $256 million, expected to fund operations through 2024. R&D expenses increased to $142.8 million from $121.3 million year-over-year. Meanwhile, the net loss for Q4 2022 was $38.8 million, down from $51.8 million in Q4 2021. Significant clinical data readouts are anticipated in the second half of 2023, which may influence the company’s growth potential and stock performance.
Dyne Therapeutics (Nasdaq: DYN) announced that CEO Joshua Brumm will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA. The presentation will be available via live webcast on Dyne's website, with a replay accessible for 30 days afterward. Dyne focuses on developing innovative therapeutics for genetically driven muscle diseases using its FORCE™ platform, targeting conditions like myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.
Dyne Therapeutics (DYN) reported third quarter 2022 financial results, highlighting the initiation of clinical trials for its lead candidates, DYNE-101 and DYNE-251. The ACHIEVE trial for DM1 and the DELIVER trial for DMD are currently underway, with data expected in the second half of 2023. As of September 30, 2022, cash and equivalents totaled $248.1 million, projected to fund operations through 2024. Net loss was $41.4 million, or $0.80 per share, showing a slight improvement from a loss of $42.6 million in Q3 2021. The FDA granted Fast Track designation for DYNE-251.
Dyne Therapeutics, a clinical-stage company focused on muscle disease treatment, will present at several key investor conferences in November 2022. These include the Credit Suisse 31st Annual Healthcare Conference on November 9, Jefferies London Healthcare Conference and Stifel 2022 Healthcare Conference on November 16, and the Piper Sandler 34th Annual Healthcare Conference on November 29. Live webcasts of these presentations will be available on Dyne's investor website for 90 days.
Dyne Therapeutics (Nasdaq: DYN) announced today the FDA has granted Fast Track designation for DYNE-251, targeting Duchenne muscular dystrophy (DMD) mutations suited for exon 51 skipping. This designation aims to expedite DYNE-251's development, which is currently evaluated in the Phase 1/2 DELIVER trial. Results are anticipated in H2 2023, focusing on safety, tolerability, and dystrophin levels. DYNE-251 aims to address a critical need in DMD treatment, enhancing access to therapies with potentially transformative effects in muscle signaling and function.
Dyne Therapeutics (DYN) presented preclinical data for its Duchenne muscular dystrophy (DMD) programs at the World Muscle Society Congress. Key findings from the DYNE-251 candidate include robust exon skipping and dystrophin expression in animal models. Notably, dystrophin levels reached 90% in the diaphragm and 77% in the heart. The FORCE platform targets exon skipping for DMD mutations, with additional conjugates for other exons. Dyne anticipates reporting clinical data from the Phase 1/2 DELIVER trial in H2 2023, focusing on safety, tolerability, and dystrophin levels.
Dyne Therapeutics, a clinical-stage company focused on muscle diseases, will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 8:00 a.m. ET. The event will provide insights into Dyne's innovative therapeutics for genetically driven diseases, including myotonic dystrophy, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event.
Dyne Therapeutics held a virtual event on Sept 12, 2022, discussing its clinical trials for DYNE-101 in myotonic dystrophy type 1 (DM1) and DYNE-251 in Duchenne muscular dystrophy (DMD). Experts shared insights into the unmet needs in these diseases. Both trials aim to report data in the second half of 2023. Dyne is extending its focus on these programs while deferring the investigational application for a program in facioscapulohumeral muscular dystrophy. As a result, the company expects its cash runway to last through 2024.
Dyne Therapeutics (Nasdaq: DYN) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 2:15 p.m. ET. The event will feature a fireside chat with management, focusing on the company’s innovative therapeutics for muscle diseases. A live webcast will be available on Dyne's website, with a replay accessible for 90 days post-event. Dyne Therapeutics specializes in developing oligonucleotide therapies targeting serious muscle disorders, utilizing its proprietary FORCE™ platform.
FAQ
What is the current stock price of Dyne Therapeutics (DYN)?
What is the market cap of Dyne Therapeutics (DYN)?
What does Dyne Therapeutics, Inc. specialize in?
What are the main diseases Dyne Therapeutics targets?
What is DYNE-101?
What is DYNE-251?
How is Dyne Therapeutics funded for their projects?
Where is Dyne Therapeutics headquartered?
When was Dyne Therapeutics founded?
What recent achievements has Dyne Therapeutics made?
What is the FORCE™ platform?
Who are the key investors and partners in Dyne Therapeutics?
